Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.
Division of Internal Medicine and Thoracic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Cancer Chemother Pharmacol. 2016 Feb;77(2):281-8. doi: 10.1007/s00280-016-2966-1. Epub 2016 Jan 20.
Creatinine clearance (Ccr) is used as a marker of renal function in cancer chemotherapy, but it is not correlated with glomerular filtration rate (GFR) after high-dose cisplatin treatment. In addition to Ccr, measured using 24-h urine collection (24-h Ccr) or Cockcroft-Gault formula (CGF), the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation and the Japanese GFR estimation equation (the Japanese equation) have been recently developed to estimate GFR for predicting renal function. However, these equations remain to be evaluated, particularly in cancer patients treated with cisplatin. Therefore, we investigated the validity of these equations for predicting the GFR in cancer patients treated with cisplatin.
GFR was measured by inulin clearance (Cin) in 50 cancer patients and compared with GFR estimated by the CKD-EPI equation, the Japanese equation, and Ccr estimated by CGF or measured by 24-h Ccr before the first and third cisplatin-containing chemotherapy cycles (considered pretreatment and posttreatment, respectively).
Before treatment, the CKD-EPI and the Japanese equations estimated GFR with higher accuracy than Ccr. Posttreatment bias values for GFR estimation using the CKD-EPI and the Japanese equations were lower than those for Ccr. The CKD-EPI and the Japanese equations were also more precise than Ccr. However, for patients with low renal function, these equations still overestimated Cin.
The CKD-EPI and the Japanese equations estimated GFR with lower bias and higher precision than Ccr pre- and postcisplatin treatment. This study is registered at UMIN: 000002167.
肌酐清除率(Ccr)被用作癌症化疗中肾功能的标志物,但在高剂量顺铂治疗后,它与肾小球滤过率(GFR)不相关。除了使用 24 小时尿液收集(24 小时 Ccr)或 Cockcroft-Gault 公式(CGF)测量的 Ccr 外,慢性肾脏病流行病学合作(CKD-EPI)方程和日本 GFR 估计方程(日本方程)最近已被开发出来,以估计 GFR 预测肾功能。然而,这些方程仍需要进行评估,特别是在接受顺铂治疗的癌症患者中。因此,我们研究了这些方程在预测接受顺铂治疗的癌症患者 GFR 方面的有效性。
通过菊粉清除率(Cin)测量 50 例癌症患者的 GFR,并与 CKD-EPI 方程、日本方程和 CGF 估计的 Ccr 或 24 小时 Ccr 测量值进行比较,这些 Ccr 分别在第一次和第三次含顺铂化疗周期前(分别考虑为预处理和治疗后)进行测量。
在治疗前,CKD-EPI 和日本方程估计 GFR 的准确性高于 Ccr。使用 CKD-EPI 和日本方程进行 GFR 估计的治疗后偏倚值低于 Ccr。CKD-EPI 和日本方程也比 Ccr 更精确。然而,对于肾功能较低的患者,这些方程仍高估了 Cin。
在顺铂治疗前后,CKD-EPI 和日本方程估计 GFR 的偏差较低,精度较高。本研究在 UMIN 注册:000002167。